JW (Cayman) Therapeutics Co. Ltd (2126.HK)
- Previous Close
2.550 - Open
2.430 - Bid 2.370 x --
- Ask 2.420 x --
- Day's Range
2.340 - 2.550 - 52 Week Range
1.580 - 3.490 - Volume
458,500 - Avg. Volume
502,279 - Market Cap (intraday)
1.003B - Beta (5Y Monthly) 2.05
- PE Ratio (TTM)
-- - EPS (TTM)
-2.020 - Earnings Date Mar 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.78
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People's Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
www.jwtherapeutics.comRecent News: 2126.HK
Performance Overview: 2126.HK
Trailing total returns as of 5/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2126.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2126.HK
Valuation Measures
Market Cap
1.06B
Enterprise Value
313.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.58
Price/Book (mrq)
0.58
Enterprise Value/Revenue
1.67
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.43%
Return on Equity (ttm)
-38.04%
Revenue (ttm)
173.86M
Net Income Avi to Common (ttm)
-768M
Diluted EPS (ttm)
-2.020
Balance Sheet and Cash Flow
Total Cash (mrq)
1.01B
Total Debt/Equity (mrq)
18.93%
Levered Free Cash Flow (ttm)
-218.11M
Research Analysis: 2126.HK
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: 2126.HK
2126.HK does not have Company Insights